Raj N, Zheng Y, Kelly V, et al. - Researchers undertook this study to assess the immunogenicity of Adrenocortical carcinomas (ACC) and involved 39 individuals in phase II study in order to estimate the clinical activity of pembrolizumab 200 mg every 3 weeks, without restriction on previous therapy. Effectiveness was associated with tumor programmed death-ligand 1 expression, microsatellite-high and/or mismatch repair deficient (MSI-H/MMR-D) status, and somatic and germline genomic correlates. It was found that MSI-H/MMR-D tumors, for which pembrolizumab was a standard therapy, were more obvious in ACC than has been identified. Moreover, in advanced ACC that was microsatellite stable, pembrolizumab gave clinically significant and durable antitumor activity with a manageable safety profile.